Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
2022; Multidisciplinary Digital Publishing Institute; Volume: 14; Issue: 23 Linguagem: Inglês
10.3390/cancers14235966
ISSN2072-6694
AutoresFriedrich Sinner, Matthias Pinter, Bernhard Scheiner, Thomas Jens Ettrich, Niklas Sturm, Maria A. Gonzalez‐Carmona, Oliver Waidmann, Fabian Finkelmeier, Vera Himmelsbach, Enrico N. De Toni, Najib Ben Khaled, Raphael Mohr, Thorben Fründt, Fabian Kütting, Florian van Bömmel, Sabine Lieb, Sebastian Krug, Dominik Bettinger, Michael Schultheiß, Leonie Jochheim, Jan Best, Christian Müller, Verena Keitel, Marino Venerito,
Tópico(s)Glycosylation and Glycoproteins Research
ResumoAtezolizumab plus bevacizumab is the standard of care for first-line systemic therapy for advanced hepatocellular carcinoma (aHCC). Data on the efficacy and safety of atezolizumab plus bevacizumab in patients with aHCC who have received prior systemic therapy are not available.
Referência(s)